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Mitotic activation of Akt signalling pathway in Han:SPRD
rats with polycystic kidney disease
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SUMMARY:
Aim: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by an imbalance between
tubular epithelial cell proliferation and apoptosis. We have previously shown that the mammalian target of
rapamycin (mTOR) signalling pathway is aberrantly activated in the cystic kidneys of Han:SPRD rats with
ADPKD. Because theAkt kinase is an upstream regulator of mTOR, we hypothesized that the activity ofAkt could
be enhanced in the kidneys of Han:SPRD rats.
Methods: Reverse transcription-polymerase chain reaction, western blot, enzyme-linked immunosorbent assay
and immunohistochemistry were used to analyse Akt expression in rat polycystic kidneys.
Results: Wild-type (+/+) and heterozygous (Cy/+) Han:SPRD rats showed constitutive expression of Akt-1, -2
and -3 mRNA by reverse transcription-polymerase chain reaction analysis with no signiﬁcant difference between
Cy/+ and +/+ kidneys. Western blotting and enzyme-linked immunosorbent assay showed a signiﬁcant increase
in phosphorylatedAkt in Cy/+ compared with +/+ kidneys. The pattern of immunoreactivity for phosphorylatedAkt
in kidney sections was the same in +/+ and in Cy/+ rats, with very low levels in interphase cells, but extremely
bright signals in mitotic cells, beginning with the onset of the prophase. The in vivo incorporation of bromo-
deoxyuridine revealed approximately a ninefold higher rate of proliferation in Cy/+ cyst epithelia compared with
normal tubule epithelia in +/+ rats, while the expression of the cell cycle marker Ki67 revealed approximately a
sixfold higher rate of proliferation. In summary, enhanced phosphorylation of Akt can be demonstrated in Cy/+
kidneys which correlates with a markedly elevated proliferation rate of epithelial cells in cysts. Mitotic but not
resting cells display strong phosphorylation of Akt.
Conclusion: Because Akt is a proximal target of mTOR, its inhibition with speciﬁc antagonists could be useful
to prevent or halt cystogenesis in ADPKD.
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Autosomal dominant polycystic kidney disease (ADPKD) is
a common monogenetic disorder affecting as many as 1 in
800 people in the general population.
1,2 The disease is char-
acterized by the formation of multiple ﬂuid-ﬁlled renal cysts
that expand over time and destroy the architecture of the
kidney. About 8–10% of all cases of chronic renal failure are
due to ADPKD, and around 50% of ADPKD patients will
develop end-stage renal disease by the time they are 60 years
of age.
1,2
Renal cyst formation is due to enhanced proliferation of
tubular epithelial cells.
3 Microdissection of cystic kidneys
has revealed that cystic enlargement is due to an increase in
the number of epithelial cells lining the cyst and not to the
stretching of the cyst epithelium.
4,5 Additionally, cultured
epithelial cells from ADPKD cysts display an enhanced
proliferation rate, and genes associated with increased
proliferation are overexpressed in cystic epithelium.
6
The mammalian target of rapamycin (mTOR), a serine/
threonine kinase, plays an important role in the transla-
tional control of gene expression during cell growth, and for
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and other environmental factors.
7 The mTOR kinase is also
a key intermediary in multiple mitogenic signalling path-
ways. Thus, mTOR plays a central role in regulating cell
proliferation, such as angiogenesis in normal tissues, and
neoplastic cell growth. An important pathway by which
growth factors and cytokines activate mTOR and its down-
stream targets is represented by the phosphoinositide
3-kinase (PI3K)/Akt pathway.
8
There is evidence that signals upstream from mTOR are
activated in ADPKD. The serine/threonine protein kinase
Akt, a downstream effector of PI3K, has emerged as a criti-
cal mediator of mTOR activity.
8 The mTOR kinase pos-
sesses two adjacent phosphorylation sites (Thr 2446 and Ser
2448), and it is known that Ser 2448 is directly phosphory-
lated by Akt.
9–11 Recently, it has been shown that Akt is
also linked to mTOR via tuberin (TSC2) which is directly
phosphorylated by Akt.
12,13
We have previously shown that mTOR is involved in the
progression of cyst development in the Han:SPRD model of
ADPKD.
14 The purpose of the present investigation was to
determine whether Akt kinase, an upstream regulator of
mTOR, is also activated in the kidney of Han:SPRD rats, a
well-characterized rodent model of ADPKD. Here we show
that phosphorylated Akt (p-Akt) is markedly increased in
heterozygous (Cy/+) Han:SPRD rats in comparison with
wild-type (+/+) rats, particularly in cells undergoing mitosis,
correlating with an increased proliferation of epithelial cells
in cysts.
METHODS
Reagents
Unless otherwise stated, all reagents used were from Sigma (St. Louis,
MO, USA).
Animals
The study was conducted in heterozygous (Cy/+) and normal littermate
control (+/+) Han:SPRD rats. Only male rats were used because the
disease progresses faster in male compared with female rats. A colony of
Han:SPRD rats was established in our animal care facility from breed-
ing pairs that were obtained from the Rat Resource & Research Center
(Columbia, MO, USA). The study protocol was approved by the regu-
latory commission for animal studies, a local government agency.
Unless otherwise stated, the rats had free access to tap water and
standard rat diet. For immunohistochemistry 8-week-old rats were
injected with 0.3 mL of bromo-deoxyuridine (BrdU) subcutaneously at
10 am on day 0 because this is the stage of cyst progression at which
proliferation is at its peak. From that time on, the drinking solution
consisted of 1 mg/mL BrdU – a synthetic analogue of thymidine – in tap
water up to sacriﬁce 4 days later between 9 am and 11 am. When
applied in vivo, BrdU is incorporated in the DNA of cycling cells,
allowing detection by speciﬁc antibodies. In addition, 16-week-old rats
were sacriﬁced and kidneys were removed for mRNA and protein
extraction. This later time point was chosen to detect more signiﬁcant
changes in RNA and protein levels, because previous results using gene
array analyses (data not shown) have revealed that expression changes
were generally more apparent in older animals. After decapsulation,
kidney slices were prepared and were stored in RNAlater (Qiagen,
Basel, Switzerland), an RNA stabilization solution for tissue, or were
snap frozen in liquid nitrogen for protein extraction. All samples were
stored at -80°C.
RNA extraction and RT-PCR for Akt
Kidney tissue was mechanically disrupted with 0.1 mm diameter
zirconia-silica beads in a Fast Prep FP120 instrument (Qbiogene,
Heidelberg, Germany). RNA isolation from this lysate was performed
with a Qiagen RNeasy mini kit (Qiagen, Basel, Switzerland), according
to the instructions of the supplier. All RNA samples were quantiﬁed by
measurement of the OD at 260 nm and were then analysed for Akt
expression by semiquantitative reverse transcription-polymerase chain
reaction (RT-PCR), using a Qiagen OneStep PCR kit (Qiagen, Basel,
Switzerland). Varying numbers of cycles (25–35) were performed to
ensure that the PCR analysis was in the linear phase of ampliﬁcation.
The primer sequences for rat Akt-1, -2 and -3 and the housekeeping
gene glyceraldehyde-3-phosphate dehydrogenase were determined
by using Primer 3 software (http://www.genome.wi.mit.edu/cgi-bin/
primer/primer3_www.cgi). RT-PCR products were resolved on 1%
agarose gels, and were stained with ethidium bromide and then
photographed with ultraviolet light.
Protein extraction
To prepare protein extracts, frozen kidney tissue samples were homog-
enized, using a Dounce homogenizer in T-PER extraction reagent
(Pierce, Rockford, IL, USA). Immediately before use, the lysis buffer
was supplemented with 1 mM PMSF, Halt™ protease and Halt™ phos-
phatase inhibitor cocktail (Pierce, Rockford, IL, USA). After centrifu-
gation at 10 000 ¥ g for 5 min, supernatants were adjusted for protein
concentration, and were used for western blotting and enzyme-linked
immunosorbent assay (ELISA).
Western blot
Frozen cell lysates were defrosted and equal amounts of protein
(0.335 mg) diluted to 0.5 mL using lysis buffer (20 mM HEPES
(pH 7.4), 150 mM NaCl, 10% (w/v) glycerol, 1% (w/v) Triton X-100,
2 mM EDTA, 10 mM sodium ﬂuoride, 1 mM phenylmethylsul-
phonyl ﬂuoride, 5 mM benzamidine, 1 mM N
a-tosyl-L-lysine
chloromethyl ketone, 20 mM leupeptin, 18 mM pepstatin, 10 mM
b-glycerophosphate, 2 mM sodium orthovanadate). Immunoprecipita-
tion was performed using polyclonal rabbit anti-Akt1/2 antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) and protein
A-sepharose CL-4B (GE Healthcare Bio-Sciences Corp., Piscataway,
NJ, USA). Samples were incubated for 3 h at 4°C with constant
mixing. The immunoprecipitates were then washed three times with
1 mL of lysis buffer and boiled in SDS-PAGE sample buffer. The
samples were analysed by SDS-PAGE (10%, reducing) and western
blotting, using polyclonal rabbit antiphospho-Akt antibody (Ser473,
Cell Signalling Technology, Danvers, MA, USA). Blots were devel-
oped using enhanced chemiluminescence (ECL kit, GE Healthcare
Bio-Sciences Corp., Piscataway, NJ, USA).
ELISA
Expression levels of total and p-Akt (phosphorylation sites Ser473 and
Thr308) were determined by sensitive and speciﬁc ELISA (Sigma, St.
Louis, MO, USA). A monoclonal capture antibody speciﬁc for Akt
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Standard dilutions and equal concentrations of samples were incubated
for 2 h at RT allowing Akt antigen to bind to the capture antibody.
After washing, a detection antibody speciﬁc for either total Akt, p-Akt
(Ser473), or p-Akt (Thr308) was added and incubated for 1 h at RT.
After washing, an anti-rabbit IgG-HRP was added. The reaction was
visualized by tetramethylbenzidine (TMB) substrate, followed by the
addition of stop solution. The optical density was measured in a multi-
well plate reader at 450 nm and is directly proportional to the concen-
tration of Akt/PKB in the sample. The values of p-Akt (Ser473) and
p-Akt (Thr308) were normalized for total Akt content.
Immunohistochemistry
Fixation and tissue treatment
The rats were anaesthetized by an intraperitoneal injection of pento-
barbital (100 mg/kg body weight) and ﬁxed by vascular perfusion.
15 The
ﬁxative contained 3% paraformaldehyde, 0.01% glutardialdehyde and
0.5% picric acid, dissolved in a 3:2 mixture of 0.1 M cacodylate buffer
(pH 7.4, added with sucrose, ﬁnal osmolality 300 mosmol) and 4%
hydroxyl ethyl starch (Fresenius Kabi, Bad Homburg, Germany) in
0.9% NaCl. The kidneys were ﬁxed for 5 min, and then rinsed by
vascular perfusion with 0.1 M cacodylate buffer for 5 min.
Immunoﬂuorescence staining
2 mm slices of ﬁxed kidney were frozen in liquid propane which was
cooled down to the temperature of liquid nitrogen, and were cut into
4 mm cryostat sections. Sections were thawed on slides and microwaved
for 10 min in 0.01 M citrate buffer at pH 6.0. After pretreatment for 1 h
in 5% normal goat serum in phosphate-buffered saline, the sections
were incubated overnight in a humidiﬁed chamber at 4°C with the
primary antibodies, diluted in phosphate-buffered saline supplemented
with 1% bovine serum albumin. p-Akt (rabbit anti-p-Akt (Thr308)),
p-S6 kinase (rabbit anti-p-S6K(Thr421/Ser424)) (both Cell Signalling
Technology, Danvers, MA, USA), BrdU (mouse anti-BrdU clone B44,
BD Biosciences Pharmingen, San Diego, CA, USA) and the prolifera-
tion marker Ki67 (rabbit anti-Ki67, Novocastra Laboratories Ltd.,
Newcastle, UK) were analysed on cryostat sections. Binding sites of the
primary antibodies were revealed with Cy3-conjugated goat-anti-rabbit
IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA).
For nuclear staining, 4′,6-diamidino-2-phenylindole (DAPI; Sigma, St.
Louis, MO, USA) was added to the working dilution of the secondary
antibodies.
Quantitative evaluation of nuclear labelling
Using the nuclear DNA-labelling of DAPI, the outer stripe and cortex
were located and micrographs were made randomly, using the 40¥
magniﬁcation of a laser scanning microscope (CLSM SP2, Leica, Man-
nheim, Germany). The surface area of tissue evaluated for each rat was
3.5 mm
2. The proximal tubule was identiﬁed by the brush border,
detectable in background ﬂuorescence. Nuclei of proximal epithelial
cells positive for BrdU, and/or Ki67 were counted in all proximal
tubules in the micrographs. DAPI ﬂuorescence was used for assessment
of the total number of nuclei in the proximal tubules. Because of the
high number of DAPI-positive cells, these were evaluated in a uniform
random systematic sample (10% sampling fraction) of the area of the
micrograph. Those parameters were evaluated separately in cystic
tubules and normal tubules.
Statistical analysis
Unless otherwise stated, data are presented as means 1 SEM and were
analysed by Student’s t-test for unpaired samples. A P-value of <0.05
was considered signiﬁcant. Statistical analysis of the data was performed
with the GraphPad Prism software (GraphPad Software Inc. San Diego,
CA, USA).
RESULTS
Renal Akt mRNA expression in Cy/+ and +/+ rats
First, we examined the kidneys of Cy/+ and wild-type +/+
rats for the presence of the three different Akt mRNAs,
using speciﬁc primers for Akt-1, -2 and -3 and RT-PCR
analysis. Figure 1 shows that all three Akt mRNA tran-
scripts were constitutively expressed. This RT-PCR analysis
did not reveal a distinct difference between healthy +/+
kidneys and polycystic Cy/+ kidneys.
Upregulation of p-Akt in Cy/+ versus +/+ rats
We then examined whether an enhanced activity of Akt
could be found in Cy/+ kidneys, as revealed by phosphory-
lation of Akt at Ser473. Total Akt was immunoprecipitated
from protein extracts of Cy/+ and +/+ kidneys, was separated
by SDS-PAGE and analysed by western blot using an
Fig. 1 Reverse transcription-polymerase chain reaction
mRNA expression of the three Akt isoforms in 16-week-old
wild-type (+/+) and heterozygous (Cy/+) rats. Akt-1, -2 and -3
mRNA transcript levels are all constitutively expressed,
with no change between the two strains. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a house-
keeping gene to ensure equal amounts of mRNA. Results are
representative of repeated experiments.
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Figure 2 shows that p-Akt (Ser473) was only weakly detect-
able in healthy 16-week-old rats. However, there was a
signiﬁcant increase in the expression levels in age-matched
heterozygous (Cy/+) rats.
We conﬁrmed the increase in Akt activity, using sensi-
tive and speciﬁc ELISA for p-Akt, examining both the
Ser473 and the Thr308 phosphorylation sites. Figure 3A
shows that there was a signiﬁcant increase in the activity
level of p-Akt at Ser473 in heterozygous (Cy/+) kidneys, as
compared with untreated wild-type (+/+) kidneys (2.5-fold
increase; P 2 0.001). Figure 3B shows that there was also a
signiﬁcant increase in levels of p-Akt at Thr308 in heterozy-
gous (Cy/+) versus untreated wild-type (+/+) rats (1.3-fold
increase; P 2 0.05). Thus, Akt phosphorylation is enhanced
at both sites in Cy/+ kidneys.
High levels of p-Akt and p-S6K in mitotic cells
We then examined the expression of p-Akt at Thr308 in
kidneys of Cy/+ and +/+ rats by immunoﬂuorescence stain-
ing. Figure 4 shows that p-Akt was detected only in a small
fraction of tubular cells. Examination of the chromatin in
the blue channel (DAPI) revealed that all of those cells
were undergoing mitosis. Immunolabelling for p-Akt was
weak to moderate in the prophase and it was restricted to
the nucleus. In the metaphase and the anaphase, the ﬂuo-
rescence was very bright and it decreased sharply in the
telophase. A very similar pattern was observed for p-S6K, a
downstream effector in the Akt pathway, with a weak signal
in the interphase, a moderate-to-strong nuclear ﬂuorescence
in the prophase and very bright ﬂuorescence in the meta-
phase and the anaphase. Figure 5 shows a typical cyst with a
cell in metaphase that is brightly positive for p-S6K.
Increased cell proliferation in cysts of Cy/+
Han:SPRD rats
In Figure 6, it can be seen that the increased proliferation
rate in the Cy/+ rat is completely attributable to cyst epi-
thelia, because in normal tubules of Cy/+ rats the incidence
of cells labelled with BrdU or Ki67 were not signiﬁcantly
different from values in +/+ rats. At 8 weeks of age the
percentage of BrdU-positive tubular cells in the cortex was
4.0% in +/+ rats, 5.3% in Cy/+ rats and reached 37.5% in
cyst epithelia. The corresponding numbers for Ki67 were
1.2%, 1.0% and 7.3%.
DISCUSSION
Here we show that the phosphorylation of Akt kinase and
hence its activity is markedly elevated in the kidney of
Han:SPRD rats with polycystic kidney disease. It has been
shown that Akt is activated by phospholipid binding and
activation loop phosphorylation at Thr308 and by phospho-
rylation within the carboxy terminus at Ser473. Phospho-
rylation of both sites is necessary for full activation.
16
Enhanced phosphorylation of Akt was evident at Ser473
and Thr308 in heterozygous Cy/+ compared with wild-type
+/+ kidneys. The most striking observation was p-Akt in
Fig. 2 SDS-PAGE and western blot analysis of protein extracts
from 16-week-old male Cy/+ and +/+ rat kidney tissue samples,
testing for phosphorylated Akt (p-Akt) (Ser473). The amount
of p-Akt was markedly increased in Cy/+ rat kidneys. Results
are representative of several repeated experiments.
Fig. 3 Protein samples from 16-week-old wild-type (+/+) and
heterozygous (Cy/+) male rats were analysed for (A) phospho-
rylated Akt (p-Akt) (Ser473) or (B) p-Akt (Thr308), using
sensitive enzyme-linked immunosorbent assay. There was a
signiﬁcant increase in both phosphorylated forms of Akt in
heterozygous Cy/+ in comparison to wild-type (+/+) rats.
*P 2 0.05, **P 2 0.001.
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activation of Akt is instrumental in mitosis in tubular
epithelial cells. Because an enhanced proliferation rate of
epithelial cells is central in cyst formation, Akt could be an
attractive target for treating ADPKD.
The detection of p-Akt in mitotic cells ﬁts with previous
studies showing the requirement for Akt activation in G2/M
transition in cell culture.
6,17 Because we observed previously
that phosphorylation of S6K, a downstream member of the
Akt signalling cascade, is increased in ADPKD rats, we were
interested in examining the distribution of p-S6K(Thr421/
Ser424) by immunoﬂuorescence. Like Akt, S6K was highly
phosphorylated throughout mitosis. Because the phospho-
rylation of S6K on the residues 421 and 424 is sensitive to
mTOR inhibition,
18,19 it is likely that the Akt/mTOR/S6K
pathway plays a role in mitosis in tubular epithelial cells.
Others and we have recently shown that mTOR and its
downstream target S6K are markedly activated in polycystic
kidney disease. Thus, we could show that S6K, a key regu-
lator of cell growth and proliferation is aberrantly phospho-
rylated in the Han:SPRD rat, a model of ADPKD.
14 Tao
et al. as well as our group could also show that rapamycin
treatment of Han:SPRD rats markedly delayed cyst growth
and renal functional deterioration in these animals.
14,20 Shil-
lingford et al. extended these ﬁndings to three mouse models
of cystic diseases with different affected genes, as well as in
human renal tissue samples from patients with ADPKD.
21 In
their landmark paper, they also provided evidence that
tuberin (TSC2), a protein that directly inhibits mTOR,
associated with polycystin 1, is the gene which is defective
in 85% of patients with ADPKD.
21 They suggested that
mutations in polycystin 1 could lead to aberrant activation
of mTOR, thus allowing phosphorylation of S6K, the
master switch of cell growth and proliferation.
The activity of the mTOR kinase may not be solely
regulated by tuberin. Renal cyst ﬂuid from PKD mice and
rodent models contain epidermal growth factor (EGF)-like
peptides in mitogenic concentrations.
22–24 EGF has also been
shown to induce proximal tubular cyst formation in murine
metanephric organ cultures.
25 It is well established in
various systems that EGF receptor (EGFR) ligation leads to
activation of phosphatidylinositol 3-kinase (PI3K). Akt
activation is one of the major downstream events of PI3K
signalling. Navé et al. showed that Akt, as part of the PI3K/
Fig. 4 Localization of phosphorylated Akt (p-Akt) (Thr308)
by immunoﬂuorescence. A normal proximal tubule (A, B) and
a cyst (C) are shown in the kidney of a 2-month-old male Cy/+
rat. (A) p-Akt positivity in a nucleus of a cell in prophase
(arrowhead). The prophase nucleus, but not the neighbouring
interphase nuclei, is positive for p-Akt. (B) the pattern of DAPI
ﬂuorescence indicates that the cell shown in A is in the
prophase (arrowhead). (C) Dual staining for p-Akt and DAPI.
Acellinthemetaphaseinacystispositiveforp-Akt(red).The
insert shows the blue channel alone (chromatin staining with
DAPI), demonstrating mitosis in the p-Akt-positive cell. The
green channel displays background ﬂuorescence of the tissue.
Bar: 10 mm in A and B, 100 mmi nC .
Fig. 5 Localization of phosphorylated S6K (p-S6K) (Thr421/
Ser424) by immunoﬂuorescence. A cell in the metaphase in a
cyst is strongly positive for p-S6K (red), whereas interphase
nuclei show only a faint signal. The insert shows the blue
channel alone (chromatin staining with DAPI), demonstrating
mitosis in the p-S6K-positive cell. The green channel displays
background ﬂuorescence of the tissue. Bar: 100 mm.
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nalling pathways involved in protein translation.
10 Thus, it
might be possible that the PI3K/Akt kinase pathway acti-
vates mTOR in a major way because of the enhanced EGFR
activation which is characteristic in ADPKD. In support of
this hypothesis is an experimental study with an EGFR
tyrosine kinase inhibitor which attenuated the development
of PKD in Han:SPRD rats.
26
In summary, we provide evidence that activation of Akt
via phosphorylation at Ser473 and Thr308 occurs in the
early phase of polycystic kidney disease in the Han:SPRD
model of ADPKD. We hypothesize that mTOR activation
by the PI3K/Akt pathway occurs in addition to the
polycystin-1-dependent regulation of mTOR via tuberin.
Although we do not know precisely which signals activate
Akt in ADPKD, it is tempting to speculate that Akt inhi-
bition with selective antagonist could have a beneﬁcial
therapeutic effect in ADPKD.
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